Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended March 31, 2026
Business Overview: A medical technology company developing non-invasive testing solutions, primarily the Intelligent Fingerprinting (IFP) Drug Screening System. The company operates globally with segments in the United Kingdom, APAC, Americas, and Rest of World.
Capital Structure Note: All share and per-share data reflect a 1-for-10 reverse stock split effected on December 15, 2025.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2026 | Nine Months Ended Mar 31, 2026 |
|---|---|---|
| Revenue | $1,060,802 | $3,069,373 |
| Gross Profit | $535,381 | $1,513,411 |
| Gross Margin | 50.5% | 49.3% |
| Net Loss (GAAP) | $(2,862,712) | $(8,523,308) |
| Net Loss Per Share (Basic/Diluted) | $(1.80) | $(7.54) |
| Cash and Cash Equivalents (End of Period) | $6,862,204 | |
| Working Capital | $5,138,618 | |
| Total Liabilities | $6,111,476 | |
| Contribution Margin (Non-GAAP) | $790,324 (74.5%) | $2,259,981 (73.6%) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 46% year-over-year for the quarter and 39% for the nine-month period, driven by the addition of 33 new customers in the quarter and 82 new customers year-to-date.
- Profitability: Gross margin improved to 50.5% (quarter) and 49.3% (nine months) compared to 46.8% and 41.3% in the prior year periods, attributed to operational efficiencies and a favorable sales mix of high-margin cartridges.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 1.8% for the quarter and 21.3% for the nine months, primarily due to increased marketing, investor relations, and legal costs associated with capital raising and the reverse stock split.
- Development Costs: Development and regulatory approval expenses surged 149% for the quarter and 4.9% for the nine months, driven by in-house R&D staffing and clinical study costs for the FDA 510(k) submission.
- Impairment: The company recorded an impairment of long-lived assets of $5,200 for the quarter and $294,127 for the nine months, related to construction in progress assets held for sale.
Guidance, Outlook, Risks, and Unusual Items
Liquidity and Going Concern
Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. Despite raising approximately $10 million in a December 2025 private placement and $3.86 million via ATM offerings through May 2026, cash reserves of $6.86 million are deemed insufficient to fund the current operating plan without additional financing.
Key Risks and Contingencies
- Australian Government Grant Repayment: Following an audit, the company owes $1,513,290 to the Australian Government, payable in 11 monthly installments. Failure to repay could result in defaults and enforcement actions.
- Intellectual Property Licensing: Development of the Biosensor Platform (BPT) is postponed pending the liquidation of Life Science Biosensor Diagnostics Pty Ltd (LSBD) and subsequent re-negotiation of IP licensing with the University of Newcastle.
- Internal Controls: Disclosure controls and procedures were deemed ineffective due to material weaknesses in the control environment, risk assessment, and monitoring. Remediation is ongoing, including the implementation of a new global accounting system (NetSuite).
- Regulatory: The company is conducting clinical studies to support a new FDA 510(k) submission for codeine detection.
Unusual Items
- Reverse Stock Split: A 1-for-10 reverse stock split was completed in December 2025 to regain compliance with Nasdaq listing requirements.
- Warrant Inducements: Significant capital was raised through warrant exercise inducements in July 2025 and January 2026, involving reduced exercise prices and the issuance of new warrants.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.86 million cash balance against the $1.51 million Australian grant repayment obligation and ongoing operating burn rate.
- Capital Raising: Monitor the status of the $100 million shelf registration and the utilization of the At-The-Market (ATM) facility to fund operations.
- IP Status: Track the liquidation timeline of LSBD and the progress of IP licensing negotiations with the University of Newcastle for the BPT platform.
- Internal Controls: Review future filings for confirmation that material weaknesses in internal controls over financial reporting have been remediated.
- Regulatory Milestones: Confirm the timeline and results of the FDA 510(k) clinical study for codeine detection.